DeepMed Research

Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis

Phase 3

Not yet recruiting

Conditions: Alcoholic Hepatitis

Interventions: Drug: N-Acetylcysteine (NAC) Treatment
Drug: Prednisolone
Drug: Placebo of N-acetylcysteine
Drug: Placebo of Prednisolone

First Posted Date: 2025-05-04

Last Posted Date: 2025-05-04

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 477

Registration Number: NCT06956482

The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)

Phase 2

Not yet recruiting

Conditions: Angina Attacks
Non Obstructive Coronary Artery Disease

Interventions: Drug: N-Acetylcysteine (NAC)
Drug: Placebo

First Posted Date: 2025-03-24

Last Posted Date: 2025-03-24

Lead Sponsor: University of Adelaide

Target Recruit Count: 25

Registration Number: NCT06890507

Locations: 🇦🇺
The Queen Elizabeth Hospital, Adelaide, South Australia, Australia

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

Not Applicable

Active, not recruiting

Conditions: Acute Liver Failure
Drug-Induced Liver Injury

Interventions: Drug: N-Acetylcysteine (NAC) Treatment
Other: Standard supportive care

First Posted Date: 2025-03-12

Last Posted Date: 2025-03-12

Lead Sponsor: Lahore General Hospital

Target Recruit Count: 62

Registration Number: NCT06872372

Locations: 🇵🇰
Lahore General Hospital, Lahore, Lahore, Punjab, Pakistan

Efficacy of Rifaximin with NAC in IBS-D

Phase 2

Not yet recruiting

Conditions: IBS (Irritable Bowel Syndrome)
IBS-D (diarrhea-predominant)

Interventions: Drug: rifaximin 66mg + N-acetylcysteine 560mg three times daily
Drug: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Drug: Placebo

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-10

Lead Sponsor: Mark Pimentel, MD

Target Recruit Count: 225

Registration Number: NCT06727422

A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine

Phase 4

Not yet recruiting

Conditions: Psychosis

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 20

Registration Number: NCT06546475

Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients

Not Applicable

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Syrup Prospan
Drug: N-Acetylcysteine

First Posted Date: 2024-04-22

Last Posted Date: 2024-08-20

Lead Sponsor: National University of Malaysia

Target Recruit Count: 100

Registration Number: NCT06377410

Locations: 🇲🇾
National University of Malaysia, Faculty of Medicine, Cheras, Kuala Lumpur, Malaysia
🇲🇾
National University of Malaysia, Cheras, Kuala Lumpur, Malaysia

Tolerability of Enteral NAC in Infants

Phase 1

Not yet recruiting

Conditions: Biliary Atresia

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2024-02-15

Last Posted Date: 2024-04-15

Lead Sponsor: Sanjiv Harpavat

Target Recruit Count: 12

Registration Number: NCT06260566

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice

Phase 3

Completed

Conditions: Hepatic and Post Hepatic Jaundice

Interventions: Drug: N-acetylcysteine

First Posted Date: 2024-02-01

Last Posted Date: 2025-04-27

Lead Sponsor: Tanta University

Target Recruit Count: 44

Registration Number: NCT06236165

Locations: 🇪🇬
Faculty of Pharmacy, Tanta University, Tanta, Egypt

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Phase 3

Recruiting

Conditions: Dry Age-related Macular Degeneration

Interventions: Drug: Aspirin 81Mg Ec Tab
Drug: Clopidogrel
Drug: N-acetylcysteine

First Posted Date: 2023-12-11

Last Posted Date: 2023-12-15

Lead Sponsor: Navamindradhiraj University

Target Recruit Count: 174

Registration Number: NCT06165068

Locations: 🇹🇭
Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University, Bangkok, Dusit, Thailand

Drug Nephrotoxicity Amelioration by N-acetylcysteine

Not Applicable

Completed

Conditions: Drug-Induced Nephropathy

Interventions: Drug: N Acetylcysteine

First Posted Date: 2023-11-08

Last Posted Date: 2024-07-05

Lead Sponsor: Helwan University

Target Recruit Count: 100

Registration Number: NCT06122311

Locations: 🇪🇬
Helwan University, Cairo, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy